Abstract：
Drug repurposing is defined as the use of approved therapeutic drugs for indications different from those for which they were originally designed. Repositioning diminishes both the time and cost for drug development by omitting the discovery stage, the analysis of absorption, distribution, metabolism, and excretion routes, as well as the studies of the biochemical and physiological effects of a new compound. Besides, drug repurposing takes advantage of the increased bioinformatics knowledge and availability of big data biology. There are many examples of drugs with repurposed indications evaluated in in vitro studies, and in pharmacological, preclinical, or retrospective clinical analyses. Here, we briefly review some of the experimental strategies and technical advances that may improve translational research in cardiovascular diseases. We also describe exhaustive research from basic science to clinical studies that culminated in the final approval of new drugs and provide examples of successful drug repurposing in the field of cardiology.
摘要：
药物再利用被定义为使用批准的治疗药物用于与最初设计的适应症不同的适应症。重新定位通过省略发现阶段来减少药物开发的时间和成本，吸收的分析，分布，新陈代谢，和排泄途径，以及对新化合物的生化和生理作用的研究。此外,药物再利用利用了越来越多的生物信息学知识和大数据生物学的可用性。在体外研究中评估了许多具有再利用适应症的药物的例子，在药理学上，临床前，或回顾性临床分析。这里,我们简要回顾了一些可能改善心血管疾病转化研究的实验策略和技术进展。我们还描述了从基础科学到临床研究的详尽研究，这些研究最终导致了新药的最终批准，并提供了在心脏病学领域成功的药物再利用的例子。
